Clinical Trial Detail

NCT ID NCT04151563
Title A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy
Recruitment Not yet recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Lucitanib + Nivolumab

Docetaxel

Cabozantinib + Nivolumab

Cabozantinib + Ipilimumab + Nivolumab

Docetaxel + Nivolumab

Docetaxel + Nivolumab + Ramucirumab

Age Groups: senior adult

Additional content available in CKB BOOST